Treatment of the primary hyperoxalurias: A new chapter

D. Milliner

doi:10.1038/sj.ki.5001821

Treatment of the primary hyperoxalurias: A new chapter

D. Milliner

Nephrology and Hypertension

Research output: Contribution to journal › Comment/debate › peer-review

21 Scopus citations

Abstract

Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.

Original language	English (US)
Pages (from-to)	1198-1200
Number of pages	3
Journal	Kidney international
Volume	70
Issue number	7
DOIs	https://doi.org/10.1038/sj.ki.5001821
State	Published - Oct 9 2006

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/sj.ki.5001821

Fingerprint Dive into the research topics of 'Treatment of the primary hyperoxalurias: A new chapter'. Together they form a unique fingerprint.

Cite this

@article{965d9aea9f664f7d9ca9b6a243cbc6e6,

title = "Treatment of the primary hyperoxalurias: A new chapter",

abstract = "Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.",

author = "D. Milliner",

year = "2006",

month = oct,

day = "9",

doi = "10.1038/sj.ki.5001821",

language = "English (US)",

volume = "70",

pages = "1198--1200",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Treatment of the primary hyperoxalurias

T2 - A new chapter

AU - Milliner, D.

PY - 2006/10/9

Y1 - 2006/10/9

N2 - Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.

AB - Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.

UR - http://www.scopus.com/inward/record.url?scp=33748923652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748923652&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5001821

DO - 10.1038/sj.ki.5001821

M3 - Comment/debate

C2 - 16988727

AN - SCOPUS:33748923652

VL - 70

SP - 1198

EP - 1200

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 7

ER -